ID

41190

Description

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01594398

Link

https://clinicaltrials.gov/show/NCT01594398

Keywords

Versions (1)
  1. 7/8/20 7/8/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 8, 2020

DOI

To request one please log in.

License

Creative Commons BY-NC 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Lung Cancer NCT01594398

English

Eligibility Lung Cancer NCT01594398

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
breast cancer patients only
Description

Breast Carcinoma Patients

Data type

boolean

Alias
UMLS CUI [1,1]
C0678222
UMLS CUI [1,2]
C0030705
postmenopausal female patients
Description

Postmenopausal state

Data type

boolean

Alias
UMLS CUI [1]
C0232970
histologically or cytologically confirmed er+ breast cancer at initial diagnosis and now has current disease progression and is a candidate to receive exemestane
Description

Estrogen receptor positive breast cancer | Disease Progression | Patient Appropriate Exemestane

Data type

boolean

Alias
UMLS CUI [1]
C2938924
UMLS CUI [2]
C0242656
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C1548787
UMLS CUI [3,3]
C0851344
nsclc patients only:
Description

Non-Small Cell Lung Carcinoma Patients

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0030705
cytologically or histologically confirmed nsclc of stage iiib or iv
Description

Non-Small Cell Lung Carcinoma TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C3258246
received 1 to 2 prior chemotherapy or chemoradiotherapy regimens for advanced nsclc (excluding erlotinib and valproic acid) and now has disease progression and is a candidate to receive erlotinib
Description

Prior Chemotherapy Quantity Advanced Lung Non-Small Cell Carcinoma | Chemoradiotherapy Quantity Advanced Lung Non-Small Cell Carcinoma | Exception Erlotinib | Exception Valproic acid | Disease Progression | Patient Appropriate Erlotinib

Data type

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C5206378
UMLS CUI [2,1]
C0436307
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C5206378
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1135135
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0042291
UMLS CUI [5]
C0242656
UMLS CUI [6,1]
C0030705
UMLS CUI [6,2]
C1548787
UMLS CUI [6,3]
C1135135
all patients:
Description

Patients All

Data type

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0444868
age ≥ 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patient must have the following laboratory parameters at study screening: hemoglobin
Description

Laboratory Results Required | Hemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C1254595
UMLS CUI [1,2]
C1514873
UMLS CUI [2]
C0518015
≥ 9.0 g/dl; unsupported platelets ≥ 100.0 10-9/l; anc ≥ 2.0 x 10-9/l; creatinine less than 2.5 times the upper limit of normal for the institution; ast and alanine transaminase (alt) < 2.5 times the upper limit of normal for the institution
Description

Platelet Count measurement | Absolute neutrophil count | Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0201899
UMLS CUI [5]
C0201836
patients may have a history of brain metastasis as long as certain criteria are met
Description

Metastatic malignant neoplasm to brain | Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2,1]
C0243161
UMLS CUI [2,2]
C1550543
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or lactating women
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
patient has rapidly progressive or life-threatening metastases.
Description

Neoplasm Metastasis Rapidly progressive | Neoplasm Metastasis Life Threatening

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C1838681
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C2826244
patient has had previous treatment with entinostat or any other hdac inhibitor including valproic acid
Description

entinostat | Histone deacetylase inhibitor | valproic acid

Data type

boolean

Alias
UMLS CUI [1]
C2743752
UMLS CUI [2]
C1512474
UMLS CUI [3]
C0042291
patient has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the investigator, such as but not limited to:
Description

Comorbidity Excludes Treatment Compliance | Comorbidity At risk Patient

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C4319828
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0030705
mi or arterial thromboembolic events within 6 months, or experiencing severe or unstable angina, new york heart association (nyha) class iii or iv disease and a qtc interval > 0.47 seconds.
Description

Myocardial Infarction | Thromboembolism | Angina Pectoris Severe | Angina, Unstable | Disease New York Heart Association Classification | Prolonged QTc interval

Data type

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0040038
UMLS CUI [3,1]
C0002962
UMLS CUI [3,2]
C0205082
UMLS CUI [4]
C0002965
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C1275491
UMLS CUI [6]
C1560305
uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, uncontrolled systemic infection.
Description

Heart failure Uncontrolled | Uncontrolled hypertension | Diabetic - poor control | Sepsis Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0018801
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C1868885
UMLS CUI [3]
C0421258
UMLS CUI [4,1]
C0243026
UMLS CUI [4,2]
C0205318
patients with another active cancer (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [cin / cervical carcinoma in situ] or melanoma in situ). prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
Description

Cancer Other | Exception Basal cell carcinoma Treated | Exception Cervical Intraepithelial Neoplasia Treated | Exception Carcinoma in situ of uterine cervix Treated | Exception Malignant melanoma in situ Treated | Exception Disease Free Duration

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [2,3]
C1522326
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0206708
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0851140
UMLS CUI [4,3]
C1522326
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0854696
UMLS CUI [5,3]
C1522326
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0012634
UMLS CUI [6,3]
C0332296
UMLS CUI [6,4]
C0449238
Back to the top of the page

Similar models

Eligibility Lung Cancer NCT01594398

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Breast Carcinoma Patients
Item
breast cancer patients only
boolean
C0678222 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
Postmenopausal state
Item
postmenopausal female patients
boolean
C0232970 (UMLS CUI [1])
Estrogen receptor positive breast cancer | Disease Progression | Patient Appropriate Exemestane
Item
histologically or cytologically confirmed er+ breast cancer at initial diagnosis and now has current disease progression and is a candidate to receive exemestane
boolean
C2938924 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0030705 (UMLS CUI [3,1])
C1548787 (UMLS CUI [3,2])
C0851344 (UMLS CUI [3,3])
Non-Small Cell Lung Carcinoma Patients
Item
nsclc patients only:
boolean
C0007131 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
Non-Small Cell Lung Carcinoma TNM clinical staging
Item
cytologically or histologically confirmed nsclc of stage iiib or iv
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Prior Chemotherapy Quantity Advanced Lung Non-Small Cell Carcinoma | Chemoradiotherapy Quantity Advanced Lung Non-Small Cell Carcinoma | Exception Erlotinib | Exception Valproic acid | Disease Progression | Patient Appropriate Erlotinib
Item
received 1 to 2 prior chemotherapy or chemoradiotherapy regimens for advanced nsclc (excluding erlotinib and valproic acid) and now has disease progression and is a candidate to receive erlotinib
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C5206378 (UMLS CUI [1,3])
C0436307 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C5206378 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1135135 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0042291 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5])
C0030705 (UMLS CUI [6,1])
C1548787 (UMLS CUI [6,2])
C1135135 (UMLS CUI [6,3])
Patients All
Item
all patients:
boolean
C0030705 (UMLS CUI [1,1])
C0444868 (UMLS CUI [1,2])
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Laboratory Results Required | Hemoglobin measurement
Item
patient must have the following laboratory parameters at study screening: hemoglobin
boolean
C1254595 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0518015 (UMLS CUI [2])
Platelet Count measurement | Absolute neutrophil count | Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
≥ 9.0 g/dl; unsupported platelets ≥ 100.0 10-9/l; anc ≥ 2.0 x 10-9/l; creatinine less than 2.5 times the upper limit of normal for the institution; ast and alanine transaminase (alt) < 2.5 times the upper limit of normal for the institution
boolean
C0032181 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
Metastatic malignant neoplasm to brain | Criteria Fulfill
Item
patients may have a history of brain metastasis as long as certain criteria are met
boolean
C0220650 (UMLS CUI [1])
C0243161 (UMLS CUI [2,1])
C1550543 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Neoplasm Metastasis Rapidly progressive | Neoplasm Metastasis Life Threatening
Item
patient has rapidly progressive or life-threatening metastases.
boolean
C0027627 (UMLS CUI [1,1])
C1838681 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C2826244 (UMLS CUI [2,2])
entinostat | Histone deacetylase inhibitor | valproic acid
Item
patient has had previous treatment with entinostat or any other hdac inhibitor including valproic acid
boolean
C2743752 (UMLS CUI [1])
C1512474 (UMLS CUI [2])
C0042291 (UMLS CUI [3])
Comorbidity Excludes Treatment Compliance | Comorbidity At risk Patient
Item
patient has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the investigator, such as but not limited to:
boolean
C0009488 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C4319828 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
Myocardial Infarction | Thromboembolism | Angina Pectoris Severe | Angina, Unstable | Disease New York Heart Association Classification | Prolonged QTc interval
Item
mi or arterial thromboembolic events within 6 months, or experiencing severe or unstable angina, new york heart association (nyha) class iii or iv disease and a qtc interval > 0.47 seconds.
boolean
C0027051 (UMLS CUI [1])
C0040038 (UMLS CUI [2])
C0002962 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0002965 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C1275491 (UMLS CUI [5,2])
C1560305 (UMLS CUI [6])
Heart failure Uncontrolled | Uncontrolled hypertension | Diabetic - poor control | Sepsis Uncontrolled
Item
uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, uncontrolled systemic infection.
boolean
C0018801 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C1868885 (UMLS CUI [2])
C0421258 (UMLS CUI [3])
C0243026 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
Cancer Other | Exception Basal cell carcinoma Treated | Exception Cervical Intraepithelial Neoplasia Treated | Exception Carcinoma in situ of uterine cervix Treated | Exception Malignant melanoma in situ Treated | Exception Disease Free Duration
Item
patients with another active cancer (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [cin / cervical carcinoma in situ] or melanoma in situ). prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0206708 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0854696 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
C0332296 (UMLS CUI [6,3])
C0449238 (UMLS CUI [6,4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial